

Help

Bloomberg

Company In Depth Fundamentals - Profile

Pfizer Inc (New York: PFE, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Website	www.pfizer.com
Number of Employees	79,000
Ticker:	PFE US

235 East 42nd Street New York, NY 10017 United States
Phone : 1-212-733-2323
Fax : 1-212-573-7851

50.61 +0.10 (0.20%)

Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	50.61	Market Cap (MM)	283,967.4
Open	50.32	Shares Out. (MM)	5,610.9
Previous Close	50.51	Float %	99.9%
Change	-0.21	Shares sold short (MM)	67,352,858.0
Change %	-0.41	Dividend Yield %	3.1
Day High/Day Low	51.3 / 50.2	Diluted EPS Excl. XO	5.7
52 Wk High/52 Wk low	61.7 / 40.9	P / Diluted EPS Before XO	9.8
Volume (MM)	19.71	Beta	0.70
Avg. Vol - 3 mo (MM)	22.24		




Financial Information (Currency: USD, in mm)			
Revenue - LTM	101,335.0	Cash & ST Invest.	31,069
EBIT - LTM	30,753.0	Total Assets	181,476.0
EBITDA - LTM	29,297.0	Total Debt	41,395.0
Net Income - LTM	29,309.0	Total Liabilities	104,014.0
Total Enterprise Value	296,632	Total Equity	77,462.0
TEV/ Total Revenue	3.3 x	Cash from Operations - LTM	34,012.0
TEV/ EBITDA	10.3 x	Cash from Investing - LTM	-20,232.0
		Cash from Financing -LTM	-13,647.0

Company Notes	
2015 Q3	
GAAP Net Income Includes: (in millions, pre-tax)	2014 Q1
A loss of \$470,000 from Asset Write Down	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$479,000 from Restructuring	A loss of \$140 from Restructuring
A loss of \$163,000 from Impairment of Intangibles	A loss of \$694 from Legal Expense
A loss of \$124,000 from Merger & Acquisition.	A loss of \$139 from Impairments and M & A Expense
A gain of \$35,000 from Disposal of assets.	A gain of \$210 from Asset Disposal, Derivatives, and other
A loss of 92,000 from various one time items.	
2015 Q2	
GAAP Net Income Includes: (in millions, pre-tax)	2013 A1
A loss of \$304,000 from Other One Time Items	GAAP Net Income Includes: (in millions, pre-tax)
A loss of \$25,000 from Asset Write Down	A loss of \$1431 from Restructuring, A gain of \$1321 from Legal Expense, A loss of \$144 from M & A Expense, A gain of \$38
A loss of \$68,000 from Merger/Acquisition Expense	from Derivatives, A loss of \$1224 from Impairments, A gain of \$125
A gain of \$ 5,000 from Investments, a gain from \$ 15,000 from disposal of asset, A loss of \$25,000 from impairment of asset	from Asset Disposal, A gain of \$195 from Sale of Investment
	A gain of \$10,623,000 from Discontinued Operations
2015 Q1	
GAAP Net Income includes, (in millions, after-tax):	2013 Q4
a loss of \$17,000 from Acquisition/Merger	GAAP Net Income Includes: (in millions, pre-tax)
a loss of \$167,000 from Various One-Time Items	A loss of \$708 from Restructuring, A loss of \$120 from Legal Expense, A loss of \$34 from M & A Expense, A gain of \$5 from
a gain of \$5,000 from Discontinued Operations	Derivatives, A loss of \$176 from Impairments, A gain of \$125
	from Assets Disposal, A gain of \$95 from Sale of Investment
	a loss of \$58,000 from Discontinued Operations
2014 A1	
GAAP Net Income includes, (in millions):	2013 Q3
a pre-tax gain of \$288,000 from Disposal of Assets	GAAP Net Income includes, (in millions, after-tax):
a pre-tax loss of \$1,630,000 from Impairment/Legal	a loss of \$54,000 from Acquisition/Merger
a pre-tax loss of \$250,000 from Restructuring/Acquisition	a loss of \$1,223,000 from Various One-Time Items
an after-tax gain of \$48,000 from Discontinued Operations	a gain of \$11,000 from Discontinued Operations

Key Board Members		
Name	Title	Organization
Ronald E Blaylock "Ron"	Founder	Blaylock & Partners Lp
	Managing Partner/Co-Founder	Gennx360 Capital Partners
	Board Member	Advantage Solutions Inc
	Board Member	Pfizer Inc
	Board Member	Carmax Inc
	Board Member	Wr Berkley Corp
	Board Member	Mebane Charitable Foundation I
Susan Desmond-Hellmann "Sue"	Board Member	Pfizer Inc
	Board Member	Pfizer Venture Investments
Suzanne Nora Johnson	Co-Chairman	Brookings Institution/The
	Chairman	Intuit Inc
	Board Member	Pfizer Inc
	Trustee	University Of Southern Califor
	Chairman	John & Mary R Markle Foundatio
	Trustee	Carnegie Institution Of Washin
	Trustee	University Of Southern Califor
	Board Member	Women'S World Banking Inc
	Board Member	Technoserve Inc
	Board Member	Council For Excellence In Govt
	Board Member	Children Now Inc
	Board Member	American Red Cross
	Board Member	Visa Intl Inc
Shantanu Narayen	Chairman/President/Ceo	Adobe Ventures Lp
	Co-Founder	Pictra Inc
	Vice Chairman	Us-India Strategic Partnership
	Chairman/Ceo	Adobe Inc
	Lead Director	Pfizer Inc
	Chairman	Adobe Foundation
Susan Hockfield	Overseer	Boston Symphony Orchestra Inc


Ticker: PFE US EQUITY		Pfizer Inc										
Period Type: Annuals		Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos										
Annuals	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY	
Key Financials	Actuals						LTM		Estimates			
	For the Fiscal Period Ending	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	03/04/2022	03/07/2022	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Total Revenue	48,851.0	52,824.0	52,546.0	53,647.0	40,905.0	USD31/12/2020	USD03/04/2022	USD03/07/2022	USD31/12/2022	23,245.8	23,245.8	
Growth Over Prior Year	(1.5%)	8.1%	(0.5%)	2.1%	(23.8%)	2.5%	94.0%	82.9%	(3.5%)	(3.5%)	(3.5%)	
Gross Profit	39,203.0	40,495.0	41,318.0	42,399.0	32,851.0	33,216.0	50,467.0	62,994.0	--	--	--	
Margin %	80.3%	76.7%	78.6%	79.0%	80.3%	--	--	--	--	--	--	
EBITDA	16,981.0	17,763.0	19,991.0	20,385.0	20,948.0	13,336.0	25,131.0	--	12,277.2	12,277.2	12,277.2	
Margin %	34.8%	33.6%	38.0%	38.0%	51.2%	--	--	--	--	52.8%	52.8%	
EBIT	11,824.0	12,006.0	13,722.0	14,001.0	14,817.0	8,166.0	19,433.0	30,753.0	11,156.9	11,156.9	11,156.9	
Margin %	24.2%	22.7%	26.1%	26.1%	36.2%	--	--	--	--	48.0%	48.0%	
Earnings from Cont. Ops.	6,975.0	7,228.0	21,353.0	11,179.0	10,738.0	7,020.0	22,459.0	29,501.0	--	--	--	
Margin %	14.3%	13.7%	40.6%	20.8%	26.3%	--	--	--	--	--	--	
Net Income	6,960.0	7,215.0	21,308.0	11,153.0	16,026.0	9,616.0	21,979.0	29,309.0	9,768.7	9,768.7	9,768.7	
Margin %	14.2%	13.7%	40.6%	20.8%	39.2%	--	--	--	--	42.0%	42.0%	
Diluted EPS Excl. Extra Items	1.1	1.2	3.5	1.9	1.9	1.2	3.9	5.1	1.6	1.6	1.6	
Growth Over Prior Year	(21.3%)	5.4%	200.9%	(47.2%)	1.6%	(34.4%)	216.9%	143.6%	21.9%	21.9%	21.9%	

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	50.61
Shares Out.	5,610.90
Market Capitalization (USD)	283,967.44
- Cash & Short Term Investments	0.00
+ Total Debt	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	296,632.44
Book Value of Common Equity	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	0.00
= Total Capital	0.00



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual	LTM	Estimates		
	03/04/2022	03/07/2022	03/04/2022	03/04/2022	03/04/2022
TEV/Total Revenue	4.2x	--	--	--	--
TEV/EBITDA	13.6x	--	--	--	--
TEV/EBIT	17.6x	--	--	--	--
P/Diluted EPS Before Extra	15.0x	10.2x	--	--	--
P/BV	4.3x	--	2.9x	2.9x	2.9x
Price/Tang BV	116.6x	--	--	--	--

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	8.9x	8.7x	8.7x	8.7x
TEV / EBITDA	10.3x	0.0x	0.0x	0.0x
Price / CF	8.3x	0.0x	0.0x	0.0x
Price / Book	3.4x	2.9x	2.9x	2.9x
Dividend Yield	3.1x	3.2x	3.2x	3.2x



Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:											
Currency	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Cost Of Goods Sold	14,076.00	9,821.00	9,586.00	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,692.00	30,821.00
Gross Profit	51,183.00	44,836.00	41,998.00	40,028.00	39,203.00	40,495.00	41,318.00	42,399.00	32,851.00	33,216.00	50,467.00
Selling General & Admin Exp.	21,762.00	16,981.00	15,537.00	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,209.00	13,505.00
R & D Exp.	9,074.00	7,482.00	6,678.00	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,405.00	13,829.00
Depreciation & Amort.	5,544.00	5,109.00	4,599.00	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,436.00	3,700.00
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	36,380.00	29,572.00	26,814.00	26,779.00	27,379.00	28,489.00	27,596.00	28,398.00	18,034.00	25,050.00	31,034.00
Operating Income	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,166.00	19,433.00
Interest Expense	1,681.00	1,522.00	1,414.00	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00
Interest Income	456.00	382.00	403.00	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00
Net Interest Exp.	1,225.00	1,140.00	1,011.00	935.00	728.00	716.00	879.00	983.00	1,348.00	1,376.00	1,255.00
Currency Exchange Gains (Loss)	-	-	-	-	806.00	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,274.00	2,882.00	(1,543.00)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(707.00)	(6,133.00)
EBT Excl. Unusual Items	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,497.00	24,311.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	12,304.00	11,242.00	15,716.00	12,240.00	8,965.00	8,351.00	12,305.00	11,885.00	11,321.00	7,497.00	24,311.00
Income Tax Expense	3,909.00	2,221.00	4,306.00	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	477.00	1,852.00
Earnings from Cont. Ops.	8,395.00	9,021.00	11,410.00	9,120.00	6,975.00	7,228.00	21,353.00	11,179.00	10,738.00	7,020.00	22,459.00
Extraord. Item & Account. Change	(1,654.00)	(5,577.00)	(10,662.00)	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,631.00)	434.00
Minority Int. in Earnings	40.00	28.00	69.00	33.00	26.00	31.00	47.00	36.00	30.00	35.00	46.00
Net Income	10,009.00	14,570.00	22,003.00	9,135.00	6,960.00	7,215.00	21,308.00	11,153.00	16,026.00	9,616.00	21,979.00
Pref. Dividends	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	10,006.00	14,568.00	22,001.00	9,133.00	6,958.00	7,213.00	21,307.00	11,152.00	16,026.00	9,616.00	21,979.00
Abnormal Losses (Gains)	6,326.00	5,985.00	1,106.00	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	3,849.00	2,533.00
Tax Effect on Abnormal Items	(1,842.00)	(2,791.00)	(344.00)	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(813.67)	(414.20)
NI to Common Excl. Extra Items	14,490.00	17,762.00	22,763.00	11,484.70	10,447.85	12,925.85	12,464.46	13,531.33	12,421.11	12,651.33	24,097.80
Per Share Items											
Basic EPS	1.28	1.96	3.23	1.44	1.13	1.18	3.57	1.90	2.88	1.73	3.92
Basic EPS Excl. Extra Items	1.07	1.21	1.67	1.43	1.13	1.18	3.57	1.90	1.92	1.26	4.00
Weighted Avg. Basic Shares Out.	7,817.00	7,442.00	6,813.00	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00
Diluted EPS	1.27	1.94	3.19	1.42	1.11	1.17	3.52	1.87	2.82	1.71	3.85
Diluted EPS Excl. Extra Items	1.06	1.20	1.65	1.41	1.11	1.17	3.52	1.86	1.89	1.24	3.93
Weighted Avg. Diluted Shares Out.	7,870.00	7,508.00	6,895.00	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00
Normalized Basic EPS	2.31	2.19	2.22	2.26	2.20	2.40	2.65	3.00	2.95	2.22	4.42
Normalized Diluted EPS	1.63	1.63	1.76	1.78	1.67	2.10	2.06	2.26	1.25	1.78	4.30
Dividends per Share	0.80	0.88	0.96	1.04	1.12	1.20	1.30	1.38	1.46	1.53	1.56
Payout Ratio %	77.97	72.84	57.68	72.65	99.57	101.55	36.43	72.73	75.93	121.68	38.82
Supplemental Items											
EBITA	20,388.00	20,373.00	19,783.00	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,602.00	23,640.00
EBIT	14,803.00	15,264.00	15,184.00	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,166.00	19,433.00
As Reported Total Revenue*	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Effective Tax Rate %	31.77	19.76	27.40	25.49	22.20	13.45	-	5.94	5.15	6.36	7.62
Normalized Net Income	12,836.00	12,185.00	12,101.00	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,020.33	24,531.80
Interest Capitalized	50.00	41.00	32.00	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	687.00	756.00	1,182.00
Stock-Based Comp., Total	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	687.00	756.00	1,182.00

Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	3,182.00	10,081.00	2,183.00	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,784.00	1,944.00
Short Term Investments	23,270.00	22,318.00	30,225.00	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00
Total Cash & ST Investments	26,452.00	32,399.00	32,408.00	36,122.00	23,290.00	17,850.00	19,992.00	18,833.00	9,646.00	12,221.00	31,069.00
Accounts & Notes Receivable	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00	11,479.00
Total Receivables	13,058.00	10,675.00	9,357.00	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,930.00	11,479.00
Inventories	6,610.00	6,076.00	6,166.00	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,046.00	9,059.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	14,697.00	15,681.00	8,313.00	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,870.00	8,086.00
Total Current Assets	60,817.00	64,831.00	56,244.00	55,595.00	43,804.00	38,949.00	41,141.00	49,926.00	32,803.00	35,067.00	59,693.00
Net Property, Plant & Equipment	15,921.00	13,213.00	12,397.00	11,760.00	13,766.00	13,318.00	13,865.00	13,385.00	14,257.00	15,293.00	17,721.00
Long-term Investments	9,814.00	14,149.00	16,406.00	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00
Deferred Charges, LT	-	1,565.00	1,554.00	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00
Other Long-Term Assets	101,450.00	92,040.00	85,500.00	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,224.00	79,195.00
Total Assets	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00
LIABILITIES											
Accrued Exp.	2,120.00	1,875.00	1,792.00	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,058.00	3,332.00
Short-term Borrowings	4,016.00	6,424.00	6,027.00	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,024.00	2,690.00
Accounts Payable	3,678.00	2,921.00	3,234.00	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,309.00	5,578.00
Curr. Income Taxes Payable	1,009.00	979.00	678.00	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00
Other Current Liabilities	18,086.00	16,987.00	11,635.00	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,582.00	14,480.00	29,806.00
Total Current Liabilities	28,909.00	29,186.00	23,366.00	21,587.00	29,398.00	31,115.00	30,427.00	31,858.00	37,303.00	25,920.00	42,672.00
Long-Term Debt	34,926.00	31,036.00	30,462.00	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,247.00	38,705.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	41,546.00	43,898.00	41,653.00	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,589.00	22,637.00
Total Liabilities	105,381.00	104,120.00	95,481.00	95,945.00	102,383.00	111,775.00	100,141.00	95,664.00	104,147.00	90,756.00	104,014.00
Pref. Stock, Non-Redeem.	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-	-
Total Pref. Equity	45.00	39.00	33.00	29.00	26.00	24.00	21.00	19.00	17.00	-	-
Minority Interest	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00
Additional Paid In Capital	71,868.00	73,056.00	77,736.00	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00
Retained Earnings	46,210.00	54,240.00	69,732.00	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	96,770.00	103,394.00
Treasury Stock	(31,801.00)	(40,122.00)	(67,923.00)	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)
Comprehensive Inc. and Other	(4,132.00)	(5,953.00)	(3,271.00)	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,638.00)	(11,688.00)	(5,897.00)
Total Common Equity	82,576.00	81,639.00	76,587.00	71,592.00	64,972.00	59,816.00	71,635.00	63,739.00	63,430.00	63,473.00	77,462.00
Total Equity	82,621.00	81,678.00	76,620.00	71,621.00	64,998.00	59,840.00	71,656.00	63,758.00	63,447.00	63,473.00	77,462.00
Total Liabilities And Equity	188,002.00	185,798.00	172,101.00	167,566.00	167,381.00	171,615.00	171,797.00	159,422.00	167,594.00	154,229.00	181,476.00
Supplemental Items											
Total Shares Out. on Filing Date	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00
Total Shares Out. on Balance Sheet Date	7,575.00	7,276.00	6,399.00	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00
Book Value/Share	10.84	11.16	11.92	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74
Tangible Book Value	(13,608.00)	(7,586.00)	(5,630.00)	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,011.00)	(14,810.00)	2,846.00
Tangible Book Value/Share	(1.80)	(1.04)	(0.88)	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.66)	0.51
Total Debt	38,942.00	37,460.00	36,489.00	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,271.00	41,395.00
Net Debt	12,490.00	5,061.00	4,081.00	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,050.00	10,326.00
Total Minority Interest	431.00	418.00	313.00	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	785.00	448.00	505.00	510.00	867.00	793.00	788.00	546.00	672.00	738.00	994.00
Work in Progress Inventory	3,514.00	3,374.00	3,445.00	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,430.00	4,424.00
Finished Goods Inventory	2,311.00	2,254.00	2,216.00	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,878.00	3,641.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	226.00	324.00	478.00	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00
Full Time Employees	103,700.00	91,500.00	77,700.00	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00

Ticker: PFE US EQUITY
 Period Type: Annuals

Sort: Ascend
 Consolidated: Yes

Accounting: Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
TEV / LTM Total Revenue	Close	2.7x	3.4x	3.9x	4.0x	4.4x	4.2x	4.6x	5.1x	6.4x	5.6x	4.2x
	Average	2.5x	2.9x	3.8x	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x
	High	2.8x	3.5x	4.2x	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	8.9x
	Low	2.2x	2.6x	3.5x	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x
TEV / LTM EBITDA	Close	7.5x	8.2x	9.3x	10.5x	12.7x	12.5x	12.0x	13.4x	12.5x	17.6x	13.6x
	Average	7.7x	7.9x	9.0x	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x
	High	8.4x	8.7x	10.0x	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x
	Low	6.7x	7.3x	8.3x	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x
TEV / LTM EBIT	Close	11.9x	12.3x	13.2x	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.5x	17.6x
	Average	12.5x	12.6x	13.5x	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	32.2x
	High	13.7x	14.0x	15.0x	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.5x	45.5x
	Low	10.9x	11.6x	12.5x	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x
Price / LTM EPS	Close	13.3x	15.4x	17.4x	17.5x	19.4x	15.5x	17.6x	19.3x	31.2x	20.7x	13.7x
	Average	12.6x	13.5x	16.9x	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	23.6x
	High	14.1x	15.1x	18.8x	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	34.4x
	Low	10.8x	12.2x	15.1x	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	20.7x	13.7x
Price / Book Value	Close	2.0x	2.2x	2.6x	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x	4.3x
	Average	1.7x	2.0x	2.5x	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x
	High	1.9x	2.3x	2.7x	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x
	Low	1.4x	1.8x	2.2x	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	--	--	--	116.6x
	Average	--	--	--	--	--	--	--	--	--	--	116.6x
	High	--	--	--	--	--	--	--	--	--	--	116.6x
	Low	--	--	--	--	--	--	--	--	--	--	116.6x
Price / Cash Flow	Close	8.4x	11.1x	11.8x	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x	10.2x
	Average	13.0x	8.5x	12.2x	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x
	High	14.5x	10.6x	13.6x	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x
	Low	7.9x	7.7x	10.9x	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x
TEV / LTM FCF	Close	9.1x	12.1x	12.7x	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x	11.1x
	Average	14.9x	9.3x	13.3x	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x
	High	16.7x	11.5x	14.7x	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	28.0x
	Low	8.6x	8.4x	11.8x	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x
Dividend Yield	Close	3.7	3.5	3.1	3.3	3.5	3.7	3.6	3.2	3.7	4.2	2.6
	Average	3.9	3.7	3.2	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7
	High	4.6	4.0	3.6	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6
	Low	3.5	3.2	2.9	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5

CAGR Over Two Years

Total Revenue	(12.7%)	(11.6%)	(14.4%)	(12.1%)	(8.8%)	5.2%	19.6%	37.8%	51.0%	59.5%	67.7%
Gross Profit	(10.5%)	(11.3%)	(12.7%)	(11.7%)	(10.3%)	(1.5%)	5.6%	18.4%	29.0%	38.8%	54.1%
EBITDA	(33.9%)	(12.8%)	(23.1%)	(15.8%)	(34.4%)	(1.3%)	8.6%	(23.1%)	54.1%	58.8%	--
EBITA	(33.9%)	(13.1%)	(24.6%)	(17.0%)	(35.5%)	(0.4%)	9.6%	(24.4%)	60.9%	62.4%	110.6%
FRIT	(52.0%)	(12.4%)	(27.8%)	(19.4%)	(46.7%)	3.1%	14.7%	(25.4%)	137.6%	76.1%	142.8%
Earnings from Cont. Ops.	--	(16.6%)	(18.1%)	(52.8%)	--	12.1%	4.9%	3.1%	--	78.1%	94.8%
Net Income	--	(2.9%)	(5.1%)	(40.2%)	--	12.1%	5.0%	3.0%	--	53.1%	68.5%
Normalized Net Income	(31.1%)	(11.9%)	(11.5%)	(22.3%)	--	6.2%	21.3%	47.6%	102.7%	78.8%	95.0%
Diluted EPS before Extra	--	(13.6%)	(15.9%)	(51.8%)	--	12.5%	4.9%	2.2%	--	76.5%	93.9%
Accounts Receivable	(9.2%)	2.2%	(3.8%)	(0.1%)	(0.6%)	1.4%	4.0%	12.3%	30.2%	15.7%	--
Inventory	(3.4%)	1.7%	3.0%	6.6%	3.5%	2.8%	4.3%	2.5%	13.2%	8.8%	--
Net PP&F	1.4%	0.7%	0.7%	1.3%	6.9%	(7.5%)	(1.9%)	(1.9%)	11.5%	3.7%	--
Total Assets	(1.2%)	0.5%	3.9%	3.3%	(1.6%)	1.1%	4.3%	2.5%	4.1%	5.1%	--
Tangible Book Value	(21.6%)	(6.8%)	(5.4%)	(5.2%)	(22.4%)	(43.8%)	(48.3%)	(94.4%)	--	--	--
Common Equity	(3.7%)	(3.7%)	(4.0%)	(4.3%)	(0.1%)	8.0%	8.5%	7.8%	10.6%	12.6%	--
Cash from Ops.	(27.1%)	25.7%	(3.9%)	(37.0%)	9.0%	63.5%	108.0%	55.0%	25.3%	44.5%	73.7%
Capital Expenditures	(9.9%)	7.9%	3.8%	1.3%	7.1%	9.7%	6.2%	5.1%	32.2%	19.7%	--
Levered Free Cash Flow	(29.2%)	29.6%	(4.9%)	(43.0%)	9.3%	79.4%	124.6%	60.8%	24.0%	48.2%	--
Unlevered Free Cash Flow	(48.1%)	--	(17.0%)	--	14.2%	--	712.2%	103.3%	50.3%	151.0%	--
Dividend per Share	6.1%	5.7%	5.7%	5.7%	5.7%	4.1%	4.1%	4.1%	4.1%	2.6%	2.6%

CAGR Over Three Years

Total Revenue	(8.5%)	(7.6%)	(8.5%)	(7.9%)	(5.3%)	4.0%	12.1%	21.9%	19.5%	25.1%	27.9%
Gross Profit	(7.0%)	(7.6%)	(7.7%)	(7.1%)	(5.7%)	0.1%	4.2%	10.0%	9.0%	13.6%	21.3%
EBITDA	(17.2%)	(9.0%)	(14.9%)	(10.0%)	(24.0%)	2.7%	7.8%	11.7%	7.6%	20.5%	--
EBITA	(17.7%)	(9.3%)	(15.9%)	(10.6%)	(25.6%)	2.5%	8.2%	11.8%	3.5%	22.3%	33.8%
EBIT	(31.1%)	(8.9%)	(17.9%)	(12.6%)	(34.2%)	5.9%	12.2%	17.7%	9.0%	28.7%	42.0%
Earnings from Cont. Ops.	(210.9%)	(7.4%)	(5.4%)	(31.5%)	(62.8%)	11.0%	12.8%	25.7%	(310.6%)	26.5%	25.0%
Net Income	(175.8%)	2.4%	4.3%	(19.7%)	(59.0%)	11.1%	12.8%	25.6%	(305.0%)	26.5%	25.2%
Normalized Net Income	(17.8%)	(4.4%)	(7.0%)	(11.5%)	(15.1%)	9.2%	15.3%	24.2%	(260.1%)	29.0%	41.9%
Diluted EPS before Extra	(216.6%)	(4.8%)	(3.4%)	(30.2%)	(62.1%)	13.4%	14.7%	27.2%	(306.9%)	26.3%	24.8%
Accounts Receivable	(6.3%)	3.6%	(1.2%)	0.0%	(1.2%)	1.4%	2.4%	5.9%	17.7%	11.3%	--
Inventory	1.4%	4.3%	4.1%	5.5%	2.0%	1.4%	3.5%	1.8%	6.5%	7.5%	--
Net PP&E	2.3%	2.0%	1.8%	2.2%	3.3%	0.1%	0.7%	0.9%	9.8%	0.8%	--
Total Assets	(0.8%)	(0.5%)	1.8%	1.3%	(3.5%)	(1.2%)	1.0%	2.2%	4.4%	5.8%	--
Tangible Book Value	(24.0%)	(14.8%)	(14.9%)	(15.2%)	(21.9%)	(34.4%)	(38.6%)	(84.6%)	(148.6%)	(143.6%)	--
Common Equity	2.0%	3.6%	3.3%	2.4%	(3.9%)	(0.7%)	0.1%	2.0%	6.8%	11.9%	--
Cash from Ops.	(13.1%)	25.5%	3.2%	(24.7%)	(7.4%)	31.8%	43.2%	27.2%	7.7%	56.8%	60.2%
Capital Expenditures	(6.2%)	7.8%	0.7%	7.6%	3.9%	12.8%	8.4%	4.5%	13.2%	11.8%	--
Levered Free Cash Flow	(14.2%)	29.8%	3.5%	(29.9%)	(8.8%)	35.6%	46.5%	29.4%	6.7%	68.3%	--
Unlevered Free Cash Flow	(28.0%)	(193.1%)	3.9%	(161.2%)	(15.2%)	(260.9%)	81.5%	43.4%	9.3%	(265.4%)	--
Dividend per Share	6.3%	5.9%	5.9%	5.9%	5.9%	4.7%	4.7%	4.7%	4.7%	3.6%	3.6%

CAGR Over Five Years

Total Revenue	(4.4%)	(1.5%)	(3.6%)	(3.2%)	(3.7%)	2.2%	7.6%	13.1%	11.8%	15.0%	16.6%
Gross Profit	(4.3%)	(2.0%)	(3.6%)	(3.5%)	(3.8%)	0.4%	3.6%	7.2%	6.3%	8.7%	13.3%
EBITDA	(12.4%)	(0.5%)	(7.4%)	(3.8%)	(12.2%)	2.1%	7.4%	11.2%	6.1%	13.7%	--
EBITA	(13.2%)	(0.5%)	(8.0%)	(4.3%)	(12.6%)	2.5%	8.1%	11.9%	7.6%	14.5%	21.4%
EBIT	(24.4%)	(0.0%)	(10.4%)	(6.1%)	(18.6%)	3.8%	10.0%	15.2%	13.1%	18.6%	26.7%
Earnings from Cont. Ops.	(196.3%)	0.9%	(0.2%)	(15.5%)	(230.7%)	9.9%	22.0%	43.2%	36.2%	20.3%	26.3%
Net Income	(177.2%)	7.1%	5.8%	(7.2%)	(237.6%)	9.9%	22.1%	43.2%	34.4%	20.3%	26.4%
Normalized Net Income	(13.0%)	2.8%	(0.9%)	(6.5%)	(2.2%)	5.2%	7.6%	20.9%	17.9%	22.8%	25.1%
Diluted EPS before Extra	(199.0%)	3.0%	1.8%	(14.0%)	(229.7%)	11.9%	24.3%	45.2%	38.9%	21.9%	27.7%
Accounts Receivable	(4.2%)	2.1%	0.4%	1.0%	(0.6%)	1.8%	3.0%	3.9%	6.9%	8.3%	--
Inventory	4.5%	7.8%	8.1%	3.9%	1.4%	2.3%	3.3%	2.9%	6.0%	6.1%	--
Net PP&E	3.9%	4.0%	4.3%	1.0%	2.1%	0.6%	0.9%	1.7%	5.9%	2.7%	--
Total Assets	0.0%	0.7%	2.0%	0.9%	(1.6%)	(0.5%)	(0.1%)	0.1%	1.1%	1.7%	--
Tangible Book Value	29.4%	28.3%	30.5%	3.7%	(7.2%)	(17.0%)	(24.0%)	(70.1%)	(157.8%)	(155.5%)	--
Common Equity	(2.4%)	(0.7%)	(0.8%)	(0.5%)	(0.5%)	1.7%	2.2%	3.6%	5.3%	7.1%	--
Cash from Ops.	(7.6%)	35.7%	(2.8%)	(16.1%)	2.8%	20.2%	25.7%	18.0%	0.6%	32.8%	27.1%
Capital Expenditures	9.9%	13.4%	12.1%	14.2%	5.1%	13.0%	6.1%	7.6%	7.6%	12.4%	--
Levered Free Cash Flow	(9.4%)	43.5%	(4.2%)	(20.2%)	2.5%	21.4%	27.4%	18.8%	(0.6%)	36.9%	--
Unlevered Free Cash Flow	(19.6%)	(184.8%)	(14.1%)	(172.0%)	1.3%	(239.3%)	44.0%	26.4%	(3.4%)	(238.4%)	--
Dividend per Share	6.7%	6.3%	6.3%	6.3%	6.3%	5.4%	5.4%	5.4%	5.4%	4.6%	4.6%

Ticker: **PFE US EQUITY** PFE US EQUITY Ascend Currency Reporting Change USD
 Period Type: **Annuals** Consolidated Yes Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE											
Revenue by Product											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
Biopharma	61,971.00	51,214.00	47,878.00	25,600.00	26,758.00	29,197.00	31,422.00	37,558.00	38,344.00	41,651.00	81,288.00
Rare Disease	3,288.00	3,443.00	3,706.00	24,005.00	22,093.00	23,627.00	21,124.00	12,484.00	2,828.00	-	-
Oncology	-	-	-	-	-	-	-	3,605.00	-	-	-
Hospital	-	-	-	-	-	-	-	-	-	-	-
Internal Medicine	-	-	-	-	-	-	-	-	-	-	-
Vaccines	-	-	-	-	-	-	-	-	-	-	-
Inflammation & Immunology (I&I)	-	-	-	-	-	-	-	-	-	-	-
Reconciling Items	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
For the Fiscal Period Ending											
Revenue	65,259.00	54,657.00	51,584.00	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,908.00	81,288.00
United States	26,933.00	21,313.00	20,274.00	19,073.00	21,704.00	26,369.00	26,026.00	25,329.00	20,593.00	21,455.00	29,746.00
Emerging Markets	16,099.00	12,545.00	11,739.00	11,719.00	11,136.00	10,420.00	11,400.00	12,651.00	8,828.00	8,370.00	20,700.00
Developed Europe	11,252.00	10,843.00	11,225.00	11,499.00	9,713.00	9,304.00	8,510.00	9,116.00	7,462.00	8,045.00	18,334.00
Developed Rest of World	10,975.00	9,956.00	8,346.00	7,314.00	6,298.00	6,731.00	6,610.00	6,551.00	4,022.00	4,038.00	12,508.00
International	-	-	-	-	-	-	-	-	-	-	-
Rare Disease	-	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	-
Hospital	-	-	-	-	-	-	-	-	-	-	-
Internal Medicine	-	-	-	-	-	-	-	-	-	-	-
Vaccines	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker: PFE US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated Yes	Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	630.00	607.00	543.00	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00
Interest Cost	1,249.00	1,165.00	1,111.00	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00
Expected Return on Plan Assets	(1,308.00)	(1,407.00)	(1,406.00)	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,321.00)	(1,379.00)
Pension Expense (Income)	994.00	926.00	928.00	402.00	1,203.00	696.00	695.00	(2.00)	331.00	70.00	(2,011.00)
Other Postretirement Cost											
Service Cost	68.00	68.00	61.00	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00
Interest Cost	195.00	182.00	166.00	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00
Expected Return on Plan Assets	(35.00)	(46.00)	(55.00)	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(36.00)	(42.40)
Other Postretirement Benefits Expense (I)	127.00	129.00	163.00	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(118.00)	(372.00)
Pension Funded Status											
Fair Value of Plan Assets	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00
Actual Return (Loss) on Plan Assets	574.00	2,132.00	2,294.00	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	2,842.00	-
Employer Contribution	2,640.00	585.00	557.00	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	1,629.00	451.00
Benefits Paid	(989.00)	(912.00)	(1,017.00)	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)
Projected Benefit Obligation	25,157.00	28,044.00	25,633.00	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00
Over(Under) Funded Pension	(6,199.00)	(7,915.00)	(4,514.00)	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)
Accumulated Benefit Obligation	19,470.00	22,391.00	18,346.00	-	-	-	-	-	-	-	-
Pension Funding Ratio	75.36	71.78	82.39	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99
Other Postretirement Funded Status											
Fair Value of Plan Assets	422.00	644.00	741.00	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00
Actual Return (Loss) on Plan Assets	9.00	85.00	98.00	45.00	(3.00)	44.00	39.00	(22.00)	50.00	69.00	-
Employer Contribution	250.00	353.00	244.00	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00
Benefits Paid	(296.00)	(274.00)	(314.00)	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	(201.00)	-
Projected Benefit Obligation	3,900.00	4,165.00	3,438.00	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00
Over(Under) Funded Post Ret Benefits	(3,478.00)	(3,521.00)	(2,697.00)	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)
Other Post-Retirement Funding Ratio	10.82	15.46	21.55	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	7.58	7.52	7.37	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80
Discount Rate used on Plan Liabilities	4.95	4.10	4.66	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.60
Rate of Compensation Increase	3.43	2.85	2.92	2.76	2.80	2.74	2.80	2.80	-	-	-
Other Postretirement Benefits											
Expected Return on Plan Assets	8.50	8.50	8.50	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80
Discount Rate used on Plan Liabilities	4.80	4.10	5.10	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90
Health Care Cost Trend Projected(next y)	7.80	7.50	7.30	7.00	-	-	-	-	-	-	-
Pension Plan Asset Allocation											
Fair Value of Plan Assets	18,958.00	20,129.00	21,119.00	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00
Asset Category - Equities %	41.12	48.03	51.65	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00
Asset Category - Debt %	31.26	33.79	30.05	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00
Asset Category - Real Estate %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Company Stock %	-	-	-	-	-	-	-	-	-	-	-
Asset Category - Cash %	12.71	3.31	2.79	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00
Asset Category - Other %	9.77	10.02	11.36	18.41	21.20	19.70	18.30	18.20	17.00	16.60	15.00
Expected Pension Payments											
Year 1	1,398.00	1,721.00	1,368.00	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00
Year 2	1,382.00	1,319.00	1,313.00	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00
Year 3	1,415.00	1,329.00	1,320.00	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00
Year 4	1,420.00	1,353.00	1,396.00	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00
Year 5	1,435.00	1,412.00	1,511.00	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00
Beyond Year 5	8,093.00	7,552.00	7,383.00	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00
Expected Postretirement Benefits											
Year 1	295.00	295.00	286.00	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00
Year 2	308.00	306.00	285.00	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00
Year 3	317.00	313.00	293.00	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00
Year 4	326.00	321.00	303.00	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00
Year 5	331.00	329.00	311.00	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00
Beyond Year 5	1,780.00	1,748.00	1,661.00	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00

Ticker: PFE US EQUITY Sort: Ascend Currency: Reporting Change: USD
 Period Type: Annuals Consolidated: Yes Accounting: Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Supplemental											
For the Fiscal Period Ending	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Options Activity											
Options Granted During Period	66.85	57.92	45.01	44.60	46.13	1.37	1.38	1.37	1.18	1.76	0.78
Options Outstanding End Of Period	429.55	382.96	299.65	249.11	232.55	186.68	150.76	103.79	88.60	75.40	44.87
Options Exercisable End of Period	273.56	225.83	163.06	122.62	109.56	105.86	108.75	100.08	85.37	71.73	41.58
Price											
Weighted Average Fair Value per Option	3.15	2.79	3.13	-	-	-	-	-	-	-	-
Avg Exercise Price (Options Outstanding)	25.31	24.00	24.33	24.05	26.41	26.86	27.27	27.69	28.39	28.31	30.20
Avg Exercise Price (Options Exercisable)	30.09	27.32	26.06	21.19	-	-	24.49	27.47	28.04	27.97	29.81
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	2.59	1.28	1.16	3.72	1.89	1.55	2.23	2.85	2.55	1.15	1.27
Stock Opt Valuation - Expected Life (Yrs)	6.25	6.50	6.50	6.50	6.75	6.75	6.75	6.75	5.13	5.12	6.75
Stock Opt Valuation - Expected Volatil (%)	25.55	23.78	19.68	19.76	18.34	21.64	18.39	20.02	18.34	20.99	26.54
Stock Opt Valuation - Dividend Yield (%)	4.14	4.10	3.45	3.18	3.19	3.85	3.69	3.73	3.27	4.36	4.51
Stock Expense											
Expense For Stock-Based Compensation	419.00	481.00	523.00	586.00	669.00	691.00	840.00	949.00	718.00	780.00	1,200.00
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-